6月26日，Ionis Pharmaceuticals盘中上涨5.32%，报81.40美元/股，成交额7554.68万美元。
消息面上，公司宣布将亚历山大病在研药物Zilganersen的美国以外全球权益授权给Recordati，获得3000万美元预付款及最高达中20%区间的年净销售额里程碑付款和特许权使用费，同时保留美国市场独立商业化权利。此外，FDA已将该药PDUFA目标审评日期确定为9月22日。
该药此前在关键性研究中达到主要终点，50mg剂量在5岁及以上患者中展现出具统计学意义的步速稳定效果，并获得FDA优先审评资格。此次授权协议标志着公司在罕见病领域的商业化路径进一步明确，美国独立上市叠加海外合作模式有望最大化药物商业价值。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.